Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: An observer-blind, phase 3 randomised clinical trial

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: An observer-blind, phase 3 randomised clinical trial

他のバージョン（1件）を表示する

Background Meningococcal conjugate vaccines protect individuals directly, but can also confer herd protection by interrupting carriage transmission. We assessed the effects of meningococcal quadrivalent glycoconjugate (MenACWY-CRM) or serogroup B (4CMenB) vaccination on meningococcal carriage rates...

詳細記述

書誌詳細
主要な著者: Read, R, Baxter, D, Chadwick, DR, Faust, SN, Finn, A, Gordon, S, Heath, P, Lewis, D, Pollard, A, Turner, D, Bazaz, R, Ganguli, A, Havelock, T, Neal, K, Okike, I, Morales-Aza, B, Patel, K, Snape, MD, Williams, J, Gilchrist, S, Gray, S, Maiden, M, Toneatto, D, Wang, H, McCarthy, M
フォーマット: Journal article
言語:English
出版事項: Lancet 2014
その他の書誌記述
要約:Background Meningococcal conjugate vaccines protect individuals directly, but can also confer herd protection by interrupting carriage transmission. We assessed the effects of meningococcal quadrivalent glycoconjugate (MenACWY-CRM) or serogroup B (4CMenB) vaccination on meningococcal carriage rates in 18-24-year-olds.

類似資料